A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass - PubMed
5 hours ago
- #obesity in older women
- #GLP-1 receptor agonists
- #sarcopenia prevention
- Obesity in women over 65 is a growing clinical challenge linked to cardiovascular disease, osteoarthritis, frailty, sleep-breathing disorders, and sarcopenia.
- GLP-1 receptor agonists (GLP-1 RAs) like semaglutide and tirzepatide show promise for weight loss and metabolic health improvement in older women.
- Concerns exist regarding GLP-1 RAs potentially exacerbating muscle loss, which could worsen sarcopenia and frailty in older women.
- Phase 3 trials indicate sustained weight loss of 10-20% in women aged ≥65, alongside cardiometabolic improvements.
- Strategies to mitigate sarcopenia include physical activity, dietary modifications, and combination therapies to preserve muscle mass during weight loss.
- The review aims to guide personalized therapeutic decisions for older women with obesity, balancing weight loss benefits with muscle preservation.